- Home
- SAR vs ATAI Comparison
SAR vs ATAI Comparison
Compare SAR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- ATAI
- Stock Information
- Founded
- SAR 2007
- ATAI 2018
- Country
- SAR United States
- ATAI Germany
- Employees
- SAR N/A
- ATAI N/A
- Industry
- SAR Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- SAR Finance
- ATAI Health Care
- Exchange
- SAR Nasdaq
- ATAI Nasdaq
- Market Cap
- SAR 402.9M
- ATAI 444.7M
- IPO Year
- SAR 2007
- ATAI 2021
- Fundamental
- Price
- SAR $25.24
- ATAI $4.57
- Analyst Decision
- SAR Hold
- ATAI Strong Buy
- Analyst Count
- SAR 4
- ATAI 3
- Target Price
- SAR $24.75
- ATAI $13.33
- AVG Volume (30 Days)
- SAR 112.5K
- ATAI 6.3M
- Earning Date
- SAR 10-07-2025
- ATAI 08-14-2025
- Dividend Yield
- SAR 11.88%
- ATAI N/A
- EPS Growth
- SAR 105.87
- ATAI N/A
- EPS
- SAR 2.47
- ATAI N/A
- Revenue
- SAR $142,495,705.00
- ATAI $2,309,000.00
- Revenue This Year
- SAR N/A
- ATAI $423.05
- Revenue Next Year
- SAR $1.97
- ATAI N/A
- P/E Ratio
- SAR $10.22
- ATAI N/A
- Revenue Growth
- SAR N/A
- ATAI 510.85
- 52 Week Low
- SAR $21.10
- ATAI $1.03
- 52 Week High
- SAR $26.49
- ATAI $4.74
- Technical
- Relative Strength Index (RSI)
- SAR 52.36
- ATAI 70.54
- Support Level
- SAR $25.20
- ATAI $3.60
- Resistance Level
- SAR $25.59
- ATAI $4.23
- Average True Range (ATR)
- SAR 0.33
- ATAI 0.33
- MACD
- SAR 0.02
- ATAI -0.01
- Stochastic Oscillator
- SAR 70.23
- ATAI 85.09
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.